NCT00879060View on ClinicalTrials.gov

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2012

Conditions
Myocardial FibrosisHypertrophic Cardiomyopathy
Interventions
DRUG

Spironolactone

spironolactone 50mg daily

DRUG

Placebo

inactive placebo pill daily

Trial Locations (1)

02111

Tufts Medical Center, Boston

All Listed Sponsors
lead

Tufts Medical Center

OTHER

NCT00879060 - Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter